Article Text

other Versions

PDF
Randomised controlled trial
Phase 3 trial with the RTS,S/AS01 malaria vaccine shows protection against clinical and severe malaria in infants and children in Africa
  1. Geoffrey Targett
  1. Faculty of Infectious and Tropical Diseases, Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK
  1. Correspondence to: Professor Geoffrey Targett, Faculty of Infectious and Tropical Diseases, Department of Disease Control, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK; geoff.targett{at}lshtm.ac.uk

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMed

Context

There is currently no licensed malaria vaccine. Protection against malaria is dependent on use of insecticide-treated nets, other vector control measures and drug treatment. These have reduced the burden of disease over the past decade, but it remains unacceptably high.1 Malaria transmission is heterogeneous and there are particular challenges presented by hotspots of transmission and by reservoirs of asymptomatic infections that serve to maintain transmission. In addition, there are growing concerns about the spread of drug resistance, and of insecticide resistance that can reduce the benefits of treated bednets or spraying.2 ,3 …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.